Breaking News Instant updates and real-time market news.

EXEL

Exelixis

$23.12

0.47 (2.08%)

17:06
02/17/17
02/17
17:06
02/17/17
17:06

Exelixis: Cabozantinib data shows treatment well tolerated, 'promising'

Exelixis announced results from a phase 1 trial of cabozantinib in combination with either nivolumab or nivolumab plus ipilimumab in patients with refractory genitourinary tumors. The primary endpoint of the trial is to determine the dose limiting toxicity and recommended phase 2 doses of the doublet and triplet combinations. The findings were presented during a poster session on February 17 at the 2017 Genitourinary Cancers Symposium, which is being held in Orlando, Florida, February 16-18, 2017. "There is a significant unmet need for treatment regimens that can slow tumor progression in advanced, intractable cancers such as metastatic urothelial carcinoma. The use of combination therapies may be a strategy that could increase anti-tumor activity in these patients," said Andrea Apolo, M.D., Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, the principal investigator of the trial. "Previously reported data from Part I of the trial showed that cabozantinib in combination with nivolumab provided an encouraging objective response rate and tolerability profile across a diverse range of genitourinary tumors. Data from Part II also demonstrate that using cabozantinib with two immunotherapy agents is well-tolerated with promising early activity. These results support the further evaluation of both regimens in these tumor types." The recommended doses for the ongoing expansion cohorts were determined to be cabozantinib 40 mg daily plus nivolumab 3 mg/kg once every 2 weeks for the doublet and cabozantinib 40 mg daily, nivolumab 3 mg/kg plus ipilimumab 1 mg/kg every 3 weeks for 4 doses, then nivolumab 3 mg/kg every 2 weeks for the triplet. "These early clinical results generated by our collaborators at the NCI-CTEP suggest that the combination of cabozantinib with either nivolumab or nivolumab and ipilimumab in patients with genitourinary malignancies is associated with an encouraging tolerability, safety and activity profile," said Michael M. Morrissey, Ph.D., president and Chief Executive Officer of Exelixis. "With these results in hand, we are committed to further examining the potential of cabozantinib in combination with a variety of immunotherapies to treat a broad range of genitourinary and other cancers."

  • 27

    Feb

EXEL Exelixis
$23.12

0.47 (2.08%)

12/21/16
PIPR
12/21/16
NO CHANGE
PIPR
Piper lays out top BioPharma picks for 2017
Piper Jaffray analysts laid out their top BioPharma picks for 2017. Analyst Richard Purkiss favors Pfizer (PFE) and Eli Lilly (LLY) as his top large pharma picks. Analyst Joshua Schimmer calls Gilead (GILD) and Alexion (ALXN) his top large cap picks. Analyst David Amsellem names Horizon Pharma (HZNP) his top specialty pharma pick. Piper's other top Biopharma picks for 2017 include ACADIA (ACAD), Aimmune (AIMT), Akorn (AKRX), Alnylam (ALNY), Axovant Sciences (AXON), Cara Therapeutics (CARA), CoLucid Pharmaceuticals (CLCD), Eale Pharmaceuticals (EGRX), Exelixis (EXEL), Ionis Pharmaceuticals (IONS), Mallinckrodt (MNK), Neurocrine (NBIX), Nektar (NKTR), Otonomy (OTIC), Reata Pharmaceuticals (RETA), Rigel Pharmaceuticals (RIGL), Ignyta (RXDX), Theravance Biopharma (TBPH), Versartis (VSAR) and Voyager Therapeutics (VYGR). The analysts look for recent momentum in BioPharma to continue in 2017. They believe innovation and potentially repatriation should lead to increased merger activity.
01/03/17
LEER
01/03/17
NO CHANGE
Target $20
LEER
Outperform
Leerink remains bullish on Exelixis in 2017
Leerink analyst Michael Schmidt remains bullish on Exelixis in 2017 and expects continued strong U.S. sales growth of Cabometyx in renal cell carcinoma while several label extension opportunities as well as Roche's (RHHBY) IO strategy for Cotellic are key sources of upside to the current valuation. The analyst reiterated an Outperform rating on Exelixis' stock and raised his price target on the shares to $20 from $16 to reflect his more bullish stance on Cabometyx label extension opportunities, as well as incrementally higher Cotellic profit share estimates following recently announced plans by Roche to initiate additional Phase 3 trials.
01/30/17
DBAB
01/30/17
NO CHANGE
DBAB
Deutsche sees 'lots to like' for Biotechnology in 2017
Deutsche Bank analyst Andrew Peters says that while pricing headwinds are likely to dominate the near-term conversation, there is a "lot to like" in 2017 in the Biotechnology space. Fundamentals, when focusing on the longer term, remain strong and present an opportunity, Peters tells investors in a research note. He lists Exelixis (EXEL), BioMarin (BMRN), Prothena (PRTA) and Neurocrine (NBIX) as among his favored stocks for 2017.
01/31/17
01/31/17
NO CHANGE

Exelixis down with licensing deal seen as impacting takeover potential
Shares of Exelixis (EXEL) are moving lower after the company last night announced a licensing agreement for the commercialization and further clinical development in Japan of cabozantinib, its oncology medicine, with Takeda Pharmaceutical (TKPYY). Deutsche Bank analyst Andrew Peters said earlier today that while Exelixis' licensing agreement is "clearly encouraging" and highlights the value of cabozantinib, the news could impact "near-term expectations regarding strategic activity, as Japanese rights would be similarly valuable to maintain." Exelixis is down 4%, or 66c, to $17.62 in afternoon trading, a sign that the deal with Takeda could be dampening investor expectations of a buyout in the near-term. The company maintaining the U.S. rights is key, Peters told investors in a research note, adding that the U.S. is core to the valuation and the company's strategic positioning. The analyst has a Buy rating on Exelixis with a $20 price target.

TODAY'S FREE FLY STORIES

BIVV

Bioverativ

$51.47

0.76 (1.50%)

10:05
12/11/17
12/11
10:05
12/11/17
10:05
Hot Stocks
Bioverativ data shows extended dosing with Alprolix provides HepB protection »

Bioverativ and Swedish…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XENT

Intersect ENT

$28.60

-1.325 (-4.43%)

10:05
12/11/17
12/11
10:05
12/11/17
10:05
Recommendations
Intersect ENT analyst commentary  »

Intersect ENT approval…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

CTL

CenturyLink

$15.62

0.9451 (6.44%)

10:04
12/11/17
12/11
10:04
12/11/17
10:04
Technical Analysis
Technical View: CenturyLink higher on Commonwealth of Pennsylvania contract »

The stock was last up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BMRN

BioMarin

$81.99

1.09 (1.35%)

10:03
12/11/17
12/11
10:03
12/11/17
10:03
Hot Stocks
BioMarin highlights new results for valoctocogene roxaparvovec at ASH »

BioMarin Pharmaceutical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Jan

  • 28

    Feb

ABBV

AbbVie

$96.13

0.18 (0.19%)

10:02
12/11/17
12/11
10:02
12/11/17
10:02
Hot Stocks
AbbVie: Ibrutinib inhibited pre-germinal center B cells in trial »

AbbVie announced new data…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALXN

Alexion

$114.46

7.68 (7.19%)

10:02
12/11/17
12/11
10:02
12/11/17
10:02
Hot Stocks
Alexion reports results from Phase 1b/2 studies of ALXN1210 »

Alexion Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

10:01
12/11/17
12/11
10:01
12/11/17
10:01
General news
JOLTS Job Openings data reported »

October JOLTS Job…

CELG

Celgene

$106.09

3.36 (3.27%)

10:00
12/11/17
12/11
10:00
12/11/17
10:00
Options
Sizable put spread in Celgene as shares see strength »

Sizable put spread in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 25

    Mar

MARK

Remark Holdings

$8.84

1.43 (19.30%)

09:59
12/11/17
12/11
09:59
12/11/17
09:59
Conference/Events
Remark Holdings management to meet with Roth Capital »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

CTL

CenturyLink

$15.47

0.795 (5.42%)

, FTR

Frontier Communications

$9.75

0.6 (6.56%)

09:55
12/11/17
12/11
09:55
12/11/17
09:55
Options
Early notable gainers among liquid option names on December 11th »

Notable gainers among…

CTL

CenturyLink

$15.47

0.795 (5.42%)

FTR

Frontier Communications

$9.75

0.6 (6.56%)

SWN

Southwestern Energy

$5.72

0.225 (4.10%)

MNK

Mallinckrodt

$22.64

0.34 (1.52%)

WYNN

Wynn Resorts

$159.54

0.62 (0.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 11

    Dec

  • 14

    Dec

ECR

Eclipse Resources

$2.36

0.21 (9.77%)

09:55
12/11/17
12/11
09:55
12/11/17
09:55
Conference/Events
Eclipse Resources to hold a conference call »

Management discusses the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

XLE

Energy Select Sector SPDR

$69.57

0.29 (0.42%)

09:54
12/11/17
12/11
09:54
12/11/17
09:54
Technical Analysis
Technical View: Energy Select Sector SPDR leads on the upside »

The Energy Select Sector…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NKE

Nike

$61.50

0.195 (0.32%)

09:51
12/11/17
12/11
09:51
12/11/17
09:51
Upgrade
Nike rating change  »

Follow-up: Nike upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Dec

IBB

iShares Nasdaq Biotechnology Index

$106.07

2.02 (1.94%)

09:50
12/11/17
12/11
09:50
12/11/17
09:50
Technical Analysis
Technical View: iShares Nasdaq Biotechnology Index breaks out »

The iShares Nasdaq…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKS

AK Steel

$5.46

0.13 (2.44%)

09:50
12/11/17
12/11
09:50
12/11/17
09:50
Options
Interest in AK Steel Mar 7 calls continues »

Interest in AK Steel Mar…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ONCE

Spark Therapeutics

$73.38

2.82 (4.00%)

09:48
12/11/17
12/11
09:48
12/11/17
09:48
Conference/Events
Spark Therapeutics to hold a pharmaceutical update conference call »

Management reviews the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

  • 12

    Jan

NKE

Nike

$61.67

0.365 (0.60%)

09:47
12/11/17
12/11
09:47
12/11/17
09:47
Upgrade
Nike rating change  »

Nike upgraded to Positive…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Dec

09:45
12/11/17
12/11
09:45
12/11/17
09:45
General news
JOLTS Job Openings to be reported at 10:00 »

October JOLTS Job…

IOTS

Adesto Technologies

$7.00

-0.45 (-6.04%)

09:44
12/11/17
12/11
09:44
12/11/17
09:44
Conference/Events
Adesto Technologies management to meet with Roth Capital »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 14

    Dec

AGIO

Agios Pharmaceuticals

$60.97

0.14 (0.23%)

09:42
12/11/17
12/11
09:42
12/11/17
09:42
Conference/Events
Agios Pharmaceuticals to hold an investor meeting »

Investor Meeting where…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

KMB

Kimberly-Clark

09:41
12/11/17
12/11
09:41
12/11/17
09:41
Technical Analysis
Technical View: Kimberly-Clark falls in early trading, analyst action »

The stock was last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKS

AK Steel

, CELG

Celgene

$106.09

3.36 (3.27%)

09:40
12/11/17
12/11
09:40
12/11/17
09:40
Options
Unusually active option classes on open December 11th »

Unusual total active…

AKS

AK Steel

CELG

Celgene

$106.09

3.36 (3.27%)

GME

GameStop

CTL

CenturyLink

X

U.S. Steel

ORCL

Oracle

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

  • 18

    Jan

  • 25

    Mar

09:40
12/11/17
12/11
09:40
12/11/17
09:40
General news
Fed funds futures are flat to lower ahead of Wednesday's FOMC »

Fed funds futures are…

ECR

Eclipse Resources

09:35
12/11/17
12/11
09:35
12/11/17
09:35
Conference/Events
Eclipse Resources to hold a conference call »

Management discusses the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BTE

Baytex Energy

09:35
12/11/17
12/11
09:35
12/11/17
09:35
Downgrade
Baytex Energy rating change  »

Baytex Energy downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.